Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis

• Published in: International journal of biological macromolecules Vol. 261; no. Pt 1; p. 129797
• Main Authors: Qi, Jianying, Guo, Zhimou, Zhu, Shenglong, Jiang, Xuan, Wu, Yuanyuan, Chen, Yingli, Hu, Fei, Xiong, Jingjing, Wu, YunZhou, Ye, Xianlong, Liang, Xinmiao
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2024
• Subjects: Animals; Diabetes Mellitus, Type 2 - drug therapy; Fibroblast growth factor 21 (FGF21); Fibroblast Growth Factors - genetics; Fibroblast Growth Factors - pharmacology; Fibroblast Growth Factors - therapeutic use; Liver; Mice; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic steatohepatitis (NASH); Obesity - drug therapy; PEGylation; Rats; Fibroblast growth factor 21 (FGF21); PEGylation; Non-alcoholic steatohepatitis (NASH)
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2024.129797

FGF21 plays an active role in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). However, the short half-life and poor stability of wild-type FGF21 limit its clinical application. Previous studies found that PEGylation can significantly increase the stability of FGF21. However, the uneven distribution of PEGylation sites in FGF21 makes it difficult to purify PEG-FGF21, thereby affecting its yield, purity, and activity. To obtain long-acting FGF21 with controlled site-specific modification, we mutated lysine residues in FGF21, resulting in PEGylation only at the N-terminus of FGF21 (mFGF21). In addition, we modified mFGF21 molecules with different PEG molecules and selected the PEG-mFGF21 moiety with the highest activity. The yield of PEG-mFGF21 in this study reached 1 g/L (purity >99 %), and the purification process was simple and efficient with strong quality controllability. The half-life of PEG-mFGF21 in rats reached 40.5–67.4 h. Pharmacodynamic evaluation in mice with high-fat, high-cholesterol- and methionine and choline deficiency-induced NASH illustrated that PEG-mFGF21 exhibited long-term efficacy in improving liver steatosis and reducing liver cell damage, inflammation, and fibrosis. Taken together, PEG-mFGF21 could represent a potential therapeutic drug for the treatment of NASH. [Display omitted]